Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01428583 · ClinicalTrials.gov registry record · Phase 3
Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 395
- Enrollment target
NCT01428583 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 395 participants.
The verdict
NCT01428583, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 395 participants
- Enrollment target
Study Summary
The study will provide information to assess the benefits versus risks of extended exposure to oxycodone HCl and naltrexone HCl extended-release capsules in a chronic noncancer pain population.
Interventions
- DRUG oxycodone HCl and naltrexone HCl extended-release capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 395 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01428583
The ClinicalTrials.gov registry entry for NCT01428583 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 395 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which oxycodone HCl and naltrexone HCl extended-release capsules is the first listed.
NCT01428583 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01428583 about?
NCT01428583 is a clinical study titled "Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain". The study will provide information to assess the benefits versus risks of extended exposure to oxycodone HCl and naltrexone HCl extended-release capsules in a chronic noncancer pain population.
What is the current status of trial NCT01428583?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 395 participants. The study started on 2010-12. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01428583?
The interventions under investigation include: oxycodone HCl and naltrexone HCl extended-release capsules (DRUG).
Who is sponsoring clinical trial NCT01428583?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.